253 related articles for article (PubMed ID: 35979719)
1.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
3. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Nguyen HA; Su Y; Zhang JY; Antanasijevic A; Caffrey M; Schalk AM; Liu L; Rondelli D; Oh A; Mahmud DL; Bosland MC; Kajdacsy-Balla A; Peirs S; Lammens T; Mondelaers V; De Moerloose B; Goossens S; Schlicht MJ; Kabirov KK; Lyubimov AV; Merrill BJ; Saunthararajah Y; Van Vlierberghe P; Lavie A
Cancer Res; 2018 Mar; 78(6):1549-1560. PubMed ID: 29343523
[TBL] [Abstract][Full Text] [Related]
4. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
Chan WK; Lorenzi PL; Anishkin A; Purwaha P; Rogers DM; Sukharev S; Rempe SB; Weinstein JN
Blood; 2014 Jun; 123(23):3596-606. PubMed ID: 24659632
[TBL] [Abstract][Full Text] [Related]
5. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
Nguyen HA; Su Y; Lavie A
J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
[TBL] [Abstract][Full Text] [Related]
6. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
7. L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review.
Sindhu R; Manonmani HK
Anticancer Agents Med Chem; 2022; 22(13):2393-2410. PubMed ID: 34994334
[TBL] [Abstract][Full Text] [Related]
8. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
9. L-Asparaginase delivery systems targeted to minimize its side-effects.
Talluri VP; Mutaliyeva B; Sharipova A; Ulaganathan V; Lanka SS; Aidarova S; Suigenbayeva A; Tleuova A
Adv Colloid Interface Sci; 2023 Jun; 316():102915. PubMed ID: 37159987
[TBL] [Abstract][Full Text] [Related]
10. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
11. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.
Blachier J; Cleret A; Guerin N; Gil C; Fanjat JM; Tavernier F; Vidault L; Gallix F; Rama N; Rossignol R; Piedrahita D; Andrivon A; Châlons-Cottavoz M; Aguera K; Gay F; Horand F; Laperrousaz B
Exp Cell Res; 2023 May; 426(2):113568. PubMed ID: 36967104
[TBL] [Abstract][Full Text] [Related]
12. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
14. Improving the Treatment of Acute Lymphoblastic Leukemia.
Radadiya A; Zhu W; Coricello A; Alcaro S; Richards NGJ
Biochemistry; 2020 Sep; 59(35):3193-3200. PubMed ID: 32786406
[TBL] [Abstract][Full Text] [Related]
15. Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.
Parmentier JH; Maggi M; Tarasco E; Scotti C; Avramis VI; Mittelman SD
Leuk Res; 2015 Jul; 39(7):757-62. PubMed ID: 25941002
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
Emadi A; Law JY; Strovel ET; Lapidus RG; Jeng LJB; Lee M; Blitzer MG; Carter-Cooper BA; Sewell D; Van Der Merwe I; Philip S; Imran M; Yu SL; Li H; Amrein PC; Duong VH; Sausville EA; Baer MR; Fathi AT; Singh Z; Bentzen SM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):217-222. PubMed ID: 29119293
[TBL] [Abstract][Full Text] [Related]
17. The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity.
Nguyen HA; Durden DL; Lavie A
Sci Rep; 2017 Jan; 7():41643. PubMed ID: 28139703
[TBL] [Abstract][Full Text] [Related]
18. Asparaginase in the treatment of non-ALL hematologic malignancies.
Emadi A; Zokaee H; Sausville EA
Cancer Chemother Pharmacol; 2014 May; 73(5):875-83. PubMed ID: 24515335
[TBL] [Abstract][Full Text] [Related]
19. Development of a bioengineered Erwinia chrysanthemi asparaginase to enhance its anti-solid tumor potential for treating gastric cancer.
Tam SY; Chung SF; Kim CF; To JC; So PK; Cheung KK; Chung WH; Wong KY; Leung YC
Int J Biol Macromol; 2023 Dec; 253(Pt 5):127742. PubMed ID: 37923039
[TBL] [Abstract][Full Text] [Related]
20. Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Asselin BL; Fisher V
Clin J Oncol Nurs; 2014 Dec; 18(6):E107-12. PubMed ID: 25427712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
